Skip to content

PEG ratio at other companies

Exelixis logo
ExelixisEXEL
0.5×+0.4×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.2×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
0.2×
Viatris logo
ViatrisVTRS
0.1×
Biogen logo
BiogenBIIB
0.4×

Other financials

Income statement

See full
Revenue$630.6M+11.0%
Operating income$563.0M+5.4%
Net income$294.7M+23.1%
EPS (diluted)$0.67+21.8%

Balance sheet

See full
Cash & equivalents$586.4M-46.1%
Total debt$9.0B+17.8%
Total equity$9.9B+1.6%
Total assets$19.8B+12.5%

Cash flow

See full
Operating cash flow$718.2M+20.5%

Valuation

See full
Market cap$23.48B+52.4%
Enterprise value$31.86B+44.6%
P/E28.4×+14.3×
P/S9.6×+2.8×

Profitability

See full
Operating margin65.1%-18.9pp
Net margin33.9%-14.4pp

Returns & leverage

See full
Return on equity8.4%-2.7pp
Debt / equity0.9×+0.1×
Current ratio2.7×+1.1×

Where this comes from

Calculated from Royalty Pharma’s reported figures.

Based on the most recent quarter.

The official record: Royalty Pharma’s 10-Q, filed August 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's peg ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Royalty Pharma's PEG ratio?
Royalty Pharma (RPRX) reported PEG ratio of 0.3× in Q2 2025.
What does PEG ratio mean?
The P/E ratio adjusted for how fast earnings are growing.
How do you interpret PEG ratio?
Around 1.0 is often cited as fairly valued for the growth on offer; below 1.0 can flag a growth bargain. Highly sensitive to the growth input and meaningless when growth is zero or negative.
How does PEG ratio compare across companies?
A rough cross-company growth-adjusted screen; treat as directional given its sensitivity to the (trailing) growth basis.